Merck & Co. acquired privately held OncoEthix for up to $375 million, its latest push into the oncology market as the pharmaceutical giant continues bolstering its research-and-development pipeline.
from WSJ.com: US Business http://ift.tt/1GvHDY8
via IFTTT
from WSJ.com: US Business http://ift.tt/1GvHDY8
via IFTTT
No comments:
Post a Comment